Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

Addressing the challenges of knowledge co-production in quality improvement: learning from the implementation of the researcher-in-residence model.

Vindrola-Padros C, Eyre L, Baxter H, Cramer H, George B, Wye L, Fulop NJ, Utley M, Phillips N, Brindle P, Marshall M.

BMJ Qual Saf. 2019 Jan;28(1):67-73. doi: 10.1136/bmjqs-2017-007127. Epub 2018 Jun 4.

2.

Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial.

Martin RM, Donovan JL, Turner EL, Metcalfe C, Young GJ, Walsh EI, Lane JA, Noble S, Oliver SE, Evans S, Sterne JAC, Holding P, Ben-Shlomo Y, Brindle P, Williams NJ, Hill EM, Ng SY, Toole J, Tazewell MK, Hughes LJ, Davies CF, Thorn JC, Down E, Davey Smith G, Neal DE, Hamdy FC; CAP Trial Group.

JAMA. 2018 Mar 6;319(9):883-895. doi: 10.1001/jama.2018.0154.

3.

The p300 and CBP Transcriptional Coactivators Are Required for β-Cell and α-Cell Proliferation.

Wong CK, Wade-Vallance AK, Luciani DS, Brindle PK, Lynn FC, Gibson WT.

Diabetes. 2018 Mar;67(3):412-422. doi: 10.2337/db17-0237. Epub 2017 Dec 7.

4.

Loss of p300 and CBP disrupts histone acetylation at the mouse Sry promoter and causes XY gonadal sex reversal.

Carré GA, Siggers P, Xipolita M, Brindle P, Lutz B, Wells S, Greenfield A.

Hum Mol Genet. 2018 Jan 1;27(1):190-198. doi: 10.1093/hmg/ddx398.

5.
6.

Crebbp loss cooperates with Bcl2 overexpression to promote lymphoma in mice.

García-Ramírez I, Tadros S, González-Herrero I, Martín-Lorenzo A, Rodríguez-Hernández G, Moore D, Ruiz-Roca L, Blanco O, Alonso-López D, Rivas JL, Hartert K, Duval R, Klinkebiel D, Bast M, Vose J, Lunning M, Fu K, Greiner T, Rodrigues-Lima F, Jiménez R, Criado FJG, Cenador MBG, Brindle P, Vicente-Dueñas C, Alizadeh A, Sánchez-García I, Green MR.

Blood. 2017 May 11;129(19):2645-2656. doi: 10.1182/blood-2016-08-733469. Epub 2017 Mar 13.

7.

The CREBBP Acetyltransferase Is a Haploinsufficient Tumor Suppressor in B-cell Lymphoma.

Zhang J, Vlasevska S, Wells VA, Nataraj S, Holmes AB, Duval R, Meyer SN, Mo T, Basso K, Brindle PK, Hussein S, Dalla-Favera R, Pasqualucci L.

Cancer Discov. 2017 Mar;7(3):322-337. doi: 10.1158/2159-8290.CD-16-1417. Epub 2017 Jan 9.

8.

Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database.

Vinogradova Y, Coupland C, Brindle P, Hippisley-Cox J.

BMJ. 2016 Jun 28;353:i3305. doi: 10.1136/bmj.i3305.

9.

Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: Is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committee.

Turner EL, Metcalfe C, Donovan JL, Noble S, Sterne JA, Lane JA, I Walsh E, Hill EM, Down L, Ben-Shlomo Y, Oliver SE, Evans S, Brindle P, Williams NJ, Hughes LJ, Davies CF, Ng SY, Neal DE, Hamdy FC, Albertsen P, Reid CM, Oxley J, McFarlane J, Robinson MC, Adolfsson J, Zietman A, Baum M, Koupparis A, Martin RM.

Br J Cancer. 2016 Jun 28;115(1):90-4. doi: 10.1038/bjc.2016.162. Epub 2016 Jun 2.

10.

Mutation of the CH1 Domain in the Histone Acetyltransferase CREBBP Results in Autism-Relevant Behaviors in Mice.

Zheng F, Kasper LH, Bedford DC, Lerach S, Teubner BJ, Brindle PK.

PLoS One. 2016 Jan 5;11(1):e0146366. doi: 10.1371/journal.pone.0146366. eCollection 2016.

11.

Patients who discontinued statin treatment: a protocol for cohort study using primary care data.

Vinogradova Y, Coupland C, Brindle P, Hippisley-Cox J.

BMJ Open. 2015 Oct 22;5(10):e008701. doi: 10.1136/bmjopen-2015-008701.

12.

Concerns on "Validation of a Data Collection Tool and Stroke Risk Predictor".

Hippisley-Cox J, Coupland C, Brindle P.

Int J Stroke. 2015 Oct;10(7):E82. doi: 10.1111/ijs.12606. No abstract available.

PMID:
26404888
13.

Combinatorial regulation of a signal-dependent activator by phosphorylation and acetylation.

Paz JC, Park S, Phillips N, Matsumura S, Tsai WW, Kasper L, Brindle PK, Zhang G, Zhou MM, Wright PE, Montminy M.

Proc Natl Acad Sci U S A. 2014 Dec 2;111(48):17116-21. doi: 10.1073/pnas.1420389111. Epub 2014 Nov 17.

14.

Genome-wide and single-cell analyses reveal a context dependent relationship between CBP recruitment and gene expression.

Kasper LH, Qu C, Obenauer JC, McGoldrick DJ, Brindle PK.

Nucleic Acids Res. 2014 Oct;42(18):11363-82. doi: 10.1093/nar/gku827. Epub 2014 Sep 23.

15.

The performance of seven QPrediction risk scores in an independent external sample of patients from general practice: a validation study.

Hippisley-Cox J, Coupland C, Brindle P.

BMJ Open. 2014 Aug 28;4(8):e005809. doi: 10.1136/bmjopen-2014-005809.

16.

Two histone/protein acetyltransferases, CBP and p300, are indispensable for Foxp3+ T-regulatory cell development and function.

Liu Y, Wang L, Han R, Beier UH, Akimova T, Bhatti T, Xiao H, Cole PA, Brindle PK, Hancock WW.

Mol Cell Biol. 2014 Nov;34(21):3993-4007. doi: 10.1128/MCB.00919-14. Epub 2014 Aug 25.

17.

T-cells null for the MED23 subunit of mediator express decreased levels of KLF2 and inefficiently populate the peripheral lymphoid organs.

Kasper LH, Fukuyama T, Brindle PK.

PLoS One. 2014 Jul 23;9(7):e102076. doi: 10.1371/journal.pone.0102076. eCollection 2014.

18.

Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP).

Turner EL, Metcalfe C, Donovan JL, Noble S, Sterne JA, Lane JA, Avery KN, Down L, Walsh E, Davis M, Ben-Shlomo Y, Oliver SE, Evans S, Brindle P, Williams NJ, Hughes LJ, Hill EM, Davies C, Ng SY, Neal DE, Hamdy FC, Martin RM; CAP trial group.

Br J Cancer. 2014 Jun 10;110(12):2829-36. doi: 10.1038/bjc.2014.242. Epub 2014 May 27.

19.

Research: increasing value, reducing waste.

Brindle P.

Lancet. 2014 Mar 29;383(9923):1125. doi: 10.1016/S0140-6736(14)60561-4. No abstract available.

PMID:
24679625
20.

A specific CBP/p300-dependent gene expression programme drives the metabolic remodelling in late stages of spermatogenesis.

Boussouar F, Goudarzi A, Buchou T, Shiota H, Barral S, Debernardi A, Guardiola P, Brindle P, Martinez G, Arnoult C, Khochbin S, Rousseaux S.

Andrology. 2014 May;2(3):351-9. doi: 10.1111/j.2047-2927.2014.00184.x. Epub 2014 Feb 13.

21.

Statins for the primary prevention of cardiovascular disease.

Ebrahim S, Taylor FC, Brindle P.

BMJ. 2014 Jan 27;348:g280. doi: 10.1136/bmj.g280. Review. No abstract available.

22.

Prox1 ablation in hepatic progenitors causes defective hepatocyte specification and increases biliary cell commitment.

Seth A, Ye J, Yu N, Guez F, Bedford DC, Neale GA, Cordi S, Brindle PK, Lemaigre FP, Kaestner KH, Sosa-Pineda B.

Development. 2014 Feb;141(3):538-47. doi: 10.1242/dev.099481.

23.

QRISK2 validation by ethnic group.

Hippisley-Cox J, Coupland C, Robson J, Brindle P.

Heart. 2014 Mar;100(5):436. doi: 10.1136/heartjnl-2013-305355. Epub 2014 Jan 8. No abstract available.

PMID:
24402770
24.

Genetic interaction between mutations in c-Myb and the KIX domains of CBP and p300 affects multiple blood cell lineages and influences both gene activation and repression.

Kasper LH, Fukuyama T, Lerach S, Chang Y, Xu W, Wu S, Boyd KL, Brindle PK.

PLoS One. 2013 Dec 10;8(12):e82684. doi: 10.1371/journal.pone.0082684. eCollection 2013.

25.

Histone posttranslational modifications and cell fate determination: lens induction requires the lysine acetyltransferases CBP and p300.

Wolf L, Harrison W, Huang J, Xie Q, Xiao N, Sun J, Kong L, Lachke SA, Kuracha MR, Govindarajan V, Brindle PK, Ashery-Padan R, Beebe DC, Overbeek PA, Cvekl A.

Nucleic Acids Res. 2013 Dec;41(22):10199-214. doi: 10.1093/nar/gkt824. Epub 2013 Sep 12.

26.

Inhibition of p300 impairs Foxp3⁺ T regulatory cell function and promotes antitumor immunity.

Liu Y, Wang L, Predina J, Han R, Beier UH, Wang LC, Kapoor V, Bhatti TR, Akimova T, Singhal S, Brindle PK, Cole PA, Albelda SM, Hancock WW.

Nat Med. 2013 Sep;19(9):1173-7. doi: 10.1038/nm.3286. Epub 2013 Aug 18.

28.

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.

Peifer M, Fernández-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, Plenker D, Leenders F, Sun R, Zander T, Menon R, Koker M, Dahmen I, Müller C, Di Cerbo V, Schildhaus HU, Altmüller J, Baessmann I, Becker C, de Wilde B, Vandesompele J, Böhm D, Ansén S, Gabler F, Wilkening I, Heynck S, Heuckmann JM, Lu X, Carter SL, Cibulskis K, Banerji S, Getz G, Park KS, Rauh D, Grütter C, Fischer M, Pasqualucci L, Wright G, Wainer Z, Russell P, Petersen I, Chen Y, Stoelben E, Ludwig C, Schnabel P, Hoffmann H, Muley T, Brockmann M, Engel-Riedel W, Muscarella LA, Fazio VM, Groen H, Timens W, Sietsma H, Thunnissen E, Smit E, Heideman DA, Snijders PJ, Cappuzzo F, Ligorio C, Damiani S, Field J, Solberg S, Brustugun OT, Lund-Iversen M, Sänger J, Clement JH, Soltermann A, Moch H, Weder W, Solomon B, Soria JC, Validire P, Besse B, Brambilla E, Brambilla C, Lantuejoul S, Lorimier P, Schneider PM, Hallek M, Pao W, Meyerson M, Sage J, Shendure J, Schneider R, Büttner R, Wolf J, Nürnberg P, Perner S, Heukamp LC, Brindle PK, Haas S, Thomas RK.

Nat Genet. 2012 Oct;44(10):1104-10. doi: 10.1038/ng.2396. Epub 2012 Sep 2.

29.

Adding systematic family history enquiry to cardiovascular disease risk assessment: clinical utility in primary care.

Robson J, Hippisley-Cox J, Brindle P.

Ann Intern Med. 2012 Jul 17;157(2):148; author reply 149. doi: 10.7326/0003-4819-157-2-201207170-00019. No abstract available.

PMID:
22801682
30.

Primary care research after the Act: why commissioners and academia need to work together.

Brindle P.

Br J Gen Pract. 2012 May;62(598):232-3. doi: 10.3399/bjgp12X641285. No abstract available.

31.

Lifetime risks of cardiovascular disease.

Coupland C, Hippisley-Cox J, Brindle P.

N Engl J Med. 2012 Apr 26;366(17):1641; author reply 1642-3. doi: 10.1056/NEJMc1202276. No abstract available.

PMID:
22533587
32.

Is histone acetylation the most important physiological function for CBP and p300?

Bedford DC, Brindle PK.

Aging (Albany NY). 2012 Apr;4(4):247-55.

33.

Atrial fibrillation and rheumatoid arthritis are cardiovascular risk factors.

Hippisley-Cox J, Coupland C, Robson J, Brindle P.

BMJ. 2012 Mar 27;344:e2259. doi: 10.1136/bmj.e2259. No abstract available.

PMID:
22453881
34.
35.

Disrupting the CH1 domain structure in the acetyltransferases CBP and p300 results in lean mice with increased metabolic control.

Bedford DC, Kasper LH, Wang R, Chang Y, Green DR, Brindle PK.

Cell Metab. 2011 Aug 3;14(2):219-30. doi: 10.1016/j.cmet.2011.06.010.

36.

GP commissioning can unlock the full potential of research within the NHS.

Brindle P.

Br J Gen Pract. 2011 Jun;61(587):381-2. doi: 10.3399/bjgp11X572652. No abstract available.

37.

CREBBP mutations in relapsed acute lymphoblastic leukaemia.

Mullighan CG, Zhang J, Kasper LH, Lerach S, Payne-Turner D, Phillips LA, Heatley SL, Holmfeldt L, Collins-Underwood JR, Ma J, Buetow KH, Pui CH, Baker SD, Brindle PK, Downing JR.

Nature. 2011 Mar 10;471(7337):235-9. doi: 10.1038/nature09727.

38.

Inactivating mutations of acetyltransferase genes in B-cell lymphoma.

Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V, Kasper LH, Lerach S, Tang H, Ma J, Rossi D, Chadburn A, Murty VV, Mullighan CG, Gaidano G, Rabadan R, Brindle PK, Dalla-Favera R.

Nature. 2011 Mar 10;471(7337):189-95. doi: 10.1038/nature09730.

39.

Subregion-specific p300 conditional knock-out mice exhibit long-term memory impairments.

Oliveira AM, Estévez MA, Hawk JD, Grimes S, Brindle PK, Abel T.

Learn Mem. 2011 Feb 23;18(3):161-9. doi: 10.1101/lm.1939811. Print 2011.

40.

Advantages of QRISK2 (2010): the key issue is ethnicity and extent of reallocation.

Hippisley-Cox J, Coupland C, Robson J, Brindle P.

Heart. 2011 Mar;97(6):515; author reply 515-6. doi: 10.1136/hrt.2010.221085. No abstract available.

PMID:
21339322
41.
42.
43.

Distinct roles of GCN5/PCAF-mediated H3K9ac and CBP/p300-mediated H3K18/27ac in nuclear receptor transactivation.

Jin Q, Yu LR, Wang L, Zhang Z, Kasper LH, Lee JE, Wang C, Brindle PK, Dent SY, Ge K.

EMBO J. 2011 Jan 19;30(2):249-62. doi: 10.1038/emboj.2010.318. Epub 2010 Dec 3.

44.

CBP/p300 double null cells reveal effect of coactivator level and diversity on CREB transactivation.

Kasper LH, Lerach S, Wang J, Wu S, Jeevan T, Brindle PK.

EMBO J. 2010 Nov 3;29(21):3660-72. doi: 10.1038/emboj.2010.235. Epub 2010 Sep 21.

45.

Target gene context influences the transcriptional requirement for the KAT3 family of CBP and p300 histone acetyltransferases.

Bedford DC, Kasper LH, Fukuyama T, Brindle PK.

Epigenetics. 2010 Jan 1;5(1):9-15. Epub 2010 Jan 27. Review.

46.

Histone acetyltransferase CBP is vital to demarcate conventional and innate CD8+ T-cell development.

Fukuyama T, Kasper LH, Boussouar F, Jeevan T, van Deursen J, Brindle PK.

Mol Cell Biol. 2009 Jul;29(14):3894-904. doi: 10.1128/MCB.01598-08. Epub 2009 May 11.

47.

Predicting risk of type 2 diabetes in England and Wales: prospective derivation and validation of QDScore.

Hippisley-Cox J, Coupland C, Robson J, Sheikh A, Brindle P.

BMJ. 2009 Mar 17;338:b880. doi: 10.1136/bmj.b880.

48.

QRISK2 vs Framingham.

Brindle P.

Practitioner. 2008 Oct;252(1711):42; author reply 42. No abstract available.

PMID:
18972800
49.

Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2.

Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A, Brindle P.

BMJ. 2008 Jun 28;336(7659):1475-82. doi: 10.1136/bmj.39609.449676.25. Epub 2008 Jun 23.

50.

Performance of the QRISK cardiovascular risk prediction algorithm in an independent UK sample of patients from general practice: a validation study.

Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Brindle P.

Heart. 2008 Jan;94(1):34-9. Epub 2007 Oct 4.

PMID:
17916661

Supplemental Content

Loading ...
Support Center